Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell International's EBIT per Share for the
three
months ended in May. 2026 was €0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in May. 2026 was €-0.07.
During the past 12 months, the average EBIT per Share Growth Rate of Cryo-Cell International was 12.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 4.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -6.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 2.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cryo-Cell International's EBIT per Share or its related term are showing as below:
FRA:ZCY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -62.8 Med: 4.5 Max: 58.7
Current: 4.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cryo-Cell International was 58.70% per year. The lowest was -62.80% per year. And the median was 4.50% per year.
FRA:ZCY's 3-Year EBIT Growth Rate is ranked worse than 62.02% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs FRA:ZCY: 4.50
Cryo-Cell International (FRA:ZCY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cryo-Cell International EBIT per Share Related Terms
Cryo-Cell International EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (FRA:ZCY) has a EBIT per Share of €-0.07 as of May. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #325 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 62%.
Is Cryo-Cell International's EBIT per Share too high?
Cryo-Cell International's current EBIT per Share is €-0.07. Based on the distribution chart, Cryo-Cell International ranks #325 out of 524 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's EBIT per Share compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #325 out of 524 companies for EBIT per Share. This places Cryo-Cell International in the lower half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current EBIT per Share is €-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.69, compared to a current price of €2.82 — trading 39.9% below its estimated fair value. The current EBIT per Share is €-0.07. Cryo-Cell International's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current EBIT per Share is €-0.07 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.82 is trading 39.9% below its estimated GF Value™ of €4.69.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for FRA:ZCY:
EBIT per Share: €-0.07
GF Value™: €4.69 vs. price of €2.82 (39.9% below fair value)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
63GF Score
Get the complete analysis for FRA:ZCY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
